Company data sheet · Ortho Clinical Diagnostics Holdings
Ortho Clinical Diagnostics Holdings: three lost years, and the economy wasn't the reason.
- Industry
- in Vitro & in Vivo Diagnostic Substances
- Headquarters
- United States
- Sources
- SEC filings (2020–2022), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
- Data as of
- October 18, 2026
- From profit to three straight losses. Ortho Clinical Diagnostics Holdings lost money every year from 2019 to 2022: $0.4 billion in all.
- It wasn't the cycle. The losses began in 2019, a year the US economy grew 2.6% and factories added jobs. When a company falls while its economy grows, look inside the company first.
- A steady bench. Ortho Clinical Diagnostics Holdings filed 8 leadership changes since 2016, fewer than 75% of large manufacturers (the median is 19).
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2019 | $1.8 billion | −$0.2 billion | |
| 2021 | $1.8 billion | −$0.2 billion | |
| 2022 | $2 billion | −$0.1 billion |
As reported in its annual filings. Losses in red.
The full data sheet · Data Plan
Everything behind these findings, ready for your board deck.
- Market reaction to disclosed decisions: 16 decision filings since 2016, each linked to the SEC, with the share return against its sector and the S&P 500 the next day and the next year (0 with market data).
- Economic context: 7 measures for the United States, every year since 2016, from the official sources.
- Peer comparison: against 953 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.